(NASDAQ: INBX) Inhibrx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.82%.
Inhibrx Biosciences's earnings in 2026 is -$140,055,000.On average, 3 Wall Street analysts forecast INBX's earnings for 2026 to be -$81,409,394, with the lowest INBX earnings forecast at -$78,216,296, and the highest INBX earnings forecast at -$83,803,487. On average, 3 Wall Street analysts forecast INBX's earnings for 2027 to be -$41,508,814, with the lowest INBX earnings forecast at -$39,881,590, and the highest INBX earnings forecast at -$42,729,962.
In 2028, INBX is forecast to generate -$14,108,936 in earnings, with the lowest earnings forecast at -$13,556,790 and the highest earnings forecast at -$14,525,237.